Progesterone supplementation

Phase 3Small molecule

MMedical University of South Carolina

Progesterone supplementation is one of 39 small molecule programs targeting Preeclampsia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PreeclampsiaRecruiting

PreeclampsiaPhase 3

Recruiting

Competition

Competitive Landscape

47 competitors in Preeclampsia

#DrugCompanyPhaseTrials

Bayer Aspirin

Bayer

Approved

23 2

Innohep

Jazz Pharmaceuticals

Approved

1 3

Zofran

Novartis

Approved

1 4

Cytotec

Pfizer

Approved

1 5

Epsom Salt

FFresenius Kabi USA, LLC

Approved

6 6

Cardene

Sun Pharmaceutical Industries, Inc.

Aldactone

Glucophage

4 9

Procardia

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

3 10

Ephedrine Sulfate

DDr. Reddys Laboratories, SA

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

ApprovedRecruiting

Preeclampsia

NCT07448597

Clinical

Trials by Indication[1]

Preeclampsia1 trial

Progesterone Supplementation for the Prevention of Preeclampsia

Recruiting·MMedical University of South Carolina·Approved·NCT07448597·642 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Progesterone supplementation. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Progesterone supplementation compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Progesterone supplementation. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Medical University of South Carolina company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: MMedical University of South Carolina

Progesterone supplementation

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Preeclampsia1 trial

References

Drug Info

Quick Facts

Related News